India's Generic Ozempic Is Here at Rs 750 a Month: What It Is, Who Can Take It, and What You Must Know First

A weekly injection that quietly became the world's most talked-about drug just got dramatically cheaper in India. And millions of people are paying attention.

Semaglutide , the active ingredient in Ozempic and Wegovy, the weight-loss and diabetes drugs that swept global attention over the last two years , lost its Indian patent on March 20, 2026. Within days, Indian pharmaceutical companies launched their own versions at prices that stunned the market. Sun Pharmaceutical launched a generic semaglutide injection for as low as Rs 750 for a weekly dose, working out to roughly Rs 3,400 per month. Natco Pharma followed with a version starting at Rs 1,290 per month. Dr Reddy's launched Obeda, its branded generic, at Rs 4,200 per month after completing its own head-to-head Phase III clinical trial against the original drug.

For context, branded Ozempic in India was retailing between Rs 8,800 and Rs 10,000 per month before the patent expired. The price has now fallen by 65 to 90 per cent, depending on which version you choose.

Over 50 generic brands are expected to hit the market in the coming months. A drug that was largely accessible only to upper-middle-class Indians is now, price-wise at least, within reach of a far larger population.

Why This Matters Specifically for India

India has a problem that is getting harder to ignore. It has the world's largest diabetic population , over 100 million people living with Type 2 diabetes. It also has the third-largest overweight and obese population globally. Both numbers are climbing, driven by sedentary urban lifestyles, processed food consumption, and genetic predisposition to metabolic conditions.

Semaglutide addresses both. It is a GLP-1 receptor agonist , essentially a drug that mimics a hormone your gut naturally produces after eating, which signals your brain that you are full. For diabetic patients, it lowers blood sugar. For overweight patients, it reduces appetite significantly, leading to meaningful weight loss in clinical trials.

The drug was not available in India before. It was simply unaffordable for most. At Rs 9,000 per month, even six months of treatment would cost more than Rs 50,000 , beyond the reach of the majority of patients who could benefit from it. With generics now starting at Rs 1,290, that calculation changes fundamentally.

Investment bank Jefferies has described this as a "magic pill moment" for India, projecting that the semaglutide market could grow to over USD 1 billion. The pharma intelligence firm Pharmarack noted that 13 Indian generic drug companies have collectively launched 26 brands in a matter of weeks. The market is moving fast.

What Ozempic and Wegovy Actually Do , Simply Explained

Semaglutide works by mimicking a hormone called GLP-1, which is released by the intestine after you eat. That hormone tells your brain you are satisfied. In people with Type 2 diabetes, the body's insulin response is impaired , semaglutide helps the pancreas release insulin more effectively in response to blood sugar rises, while also slowing how quickly food leaves the stomach, reducing blood sugar spikes.

For people without diabetes who are overweight or obese, the appetite-suppressing effect is the primary benefit. Clinical trials showed an average weight loss of 10 to 15 per cent of body weight over 68 weeks when combined with lifestyle changes. That is not minor. For someone weighing 90 kilograms, that could mean losing 9 to 13 kilograms sustainably , something diet and exercise alone rarely achieve for people with metabolic conditions.

The injection is administered once a week using a simple pen device, subcutaneously , meaning just under the skin, typically on the abdomen. Most people start on a low dose for 4 to 8 weeks before moving to a higher maintenance dose, to allow the body to adjust and reduce side effects.

Read More: Russia Launches Progress MS-34 Cargo Ship to the ISS, Delivering Over 2.5 Tonnes of Vital Supplies

Which Indian Brands Are Available and What Do They Cost

The landscape is already crowded and still expanding. Here is where things stand as of May 2026.

Sun Pharma's generic is among the cheapest available, starting at Rs 750 per weekly dose , approximately Rs 3,400 per month. Dr Reddy's Obeda is available at Rs 4,200 per month for both 2mg and 4mg strengths and is notable for having completed its own Phase III efficacy trial in India with 312 participants, confirming non-inferior performance compared to the original drug. Natco Pharma has a version starting at Rs 1,290 per month, the lowest in the market currently.

Read More: Russia Launches Progress MS-34 Cargo Ship to the ISS, Delivering Over 2.5 Tonnes of Vital Supplies

Novo Nordisk, the original manufacturer, reduced its own branded price to Rs 5,660 per month from April 1, 2026 , a significant cut from Rs 8,800 to 10,000, though still higher than Indian generics. Novo's Wegovy is being launched under the brand name Poviztra through a partnership with Emcure Pharma.

Other major names with products in the market or awaiting DCGI approval include Torrent Pharmaceuticals, Cipla, Zydus Life Sciences, and Biocon. Analysts expect pricing to consolidate around Rs 1,500 to 4,000 per month as competition intensifies.

The Mistakes People Are Already Making With Semaglutide

The biggest mistake is treating this as a straightforward over-the-counter purchase. Semaglutide requires a prescription in India. It is a regulated drug, not a supplement. Taking it without medical supervision , especially at the wrong dose or without screening for contraindications , carries real risks.

The most common side effects are nausea, vomiting, diarrhoea, and constipation, particularly in the early weeks. These typically reduce as the body adjusts, but they can be severe. More seriously, semaglutide is not appropriate for people with a personal or family history of medullary thyroid carcinoma, or for those with certain pancreatic conditions.

The second mistake is expecting the drug to work without lifestyle changes. Clinical trials consistently show the best results when semaglutide is used alongside dietary modification and increased physical activity. People who discontinue the drug without building sustainable habits typically regain a significant portion of lost weight within a year.

The third mistake , and this is already happening widely , is buying from unverified online sources. The flood of new brands has also opened the door to counterfeit products. Always purchase from a licensed pharmacy with a valid prescription, and verify that the product carries DCGI approval.

Read More: Core Member Sandeep Pathak's Exit from AAP Hits Party the Most , And Here Is Why

What Doctors Are Saying and Who Should Actually Consider This Drug

Physicians who work in diabetes and obesity management are broadly welcoming the price reduction but urging caution about widespread casual use.

The DCGI-approved indication in India for semaglutide is Type 2 diabetes management. The same molecule sold as Wegovy for obesity treatment is not yet formally approved in India specifically for weight loss as of this writing, so prescriptions for weight loss purposes exist in a somewhat grey area currently. Patients should have a clear conversation with their doctor about their specific medical history, current medications, and goals before starting treatment.

For people with Type 2 diabetes who are not achieving adequate glycaemic control with current medications, semaglutide is a genuinely powerful addition to treatment options. For overweight or obese individuals without diabetes who are considering it purely for weight loss, the medical case needs to be evaluated individually.

Closing Thoughts

A drug that changed how the world thinks about obesity and metabolic disease has just become accessible to a country where those conditions affect tens of millions of people. That is not a small thing.

What India does with this moment , whether it is channelled into thoughtful, medically supervised treatment that genuinely improves population health, or whether it becomes a poorly regulated consumption trend driven by social media pressure and vanity , will be decided in the next 12 to 24 months.

The price barrier is falling. The medical infrastructure to support widespread safe use needs to catch up equally fast.

Disclaimer: This article is based on information available across the web. Parchar Manch does not take responsibility for its complete accuracy, as the content could not be fully verified. 

Read More: India's Forex Reserves Jump By Over $2 Billion To $703.3 Billion Amid Iran War , What This Means For You